⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

February 10, 2021Journal of the American Society of NephrologyOpen Access

Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study

View Full Paper

Ask AI

Bookmark

Share

Abstract

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With CKD, Not on Dialysis, NCT02174627.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fishbane et al. (2021) studied this question.

synapsesocial.com/papers/69d774e3b843b2be9948fd92 https://doi.org/10.1681/asn.2020081150

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKDOriginal Research · 2016 · 297 citations
2Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKDHuman Clinical Trial · 2017 · 452 citations
3Anemia and iron deficiency among chronic kidney disease Stages 3–5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treatedCross-Sectional Study · 2019 · 134 citations
4Oxygen sensing and adaptability won the 2019 Nobel Prize in Physiology or medicineOriginal Research · 2019 · 62 citations
5Anemia and clinical outcomes in patients with non-dialysis dependent or dialysis dependent severe chronic kidney disease: a Danish population-based studyCohort Study · 2019 · 80 citations